Sk Biopharmaceuticals Co., Ltd.

Seoul National University

Hyo Jun Jung

Ji Won Lee

Ji Yeon Kim

Ju Young Lee

Chan Mi Joung

Eun Ju Choi

Young Koo Jang

Cheol Young Maeng

Nahm Ryune Cho

Yong Je Shin

Jin Yong Chung

Hye Kyung Min

Eun Ju Ryu

Jong Sil Park

Seung Mo Ham

Seung Nam Han

Chun Eung Park

Soo Bong Cha

Yong Gil Kim

Tae Young Na

Eun Jin Kim

Hyeung Geun Park

Ho Young Son

Mi Ock Lee

Suck Chang Hong

The present disclosure provides a compound of Chemical Formula (1) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same: The compound of Chemical Formula (1) or pharmaceutically acceptable salt thereof acts as a positive allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5), thereby being useful in the prevention or treatment of disorder mediated by glutamate dysfunction and mGluR5.

Imidazopyrimidine and imidazotriazine derivative, and pharmaceutical composition comprising the same

The present disclosure provides a compound of Chemical Formula (1) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same:  The compound of Chemical Formula (1) or pharmaceutically acceptable salt thereof acts as a positive allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5), thereby being useful in the prevention or treatment of disorder mediated by glutamate dysfunction and mGluR5.

Provided is a compound activating ROR&#x3b1; gene, particularly a JC1 compound containing CGP52608 thiazolidinedione as a lead substance, and a pharmaceutically acceptable salt thereof. The compound is a lipid accumulation inhibitor and applicable to the treatment of metabolic diseases or inflammatory diseases.

Thiourea derivatives as activators of ROR&#x3b1; and pharmaceutical composition containing same

Growing community of inventors

Daejeon, South Korea

Hyo Jun Jung